MHealth Incentivized Adherence Plus Patient Navigation

Last updated: January 28, 2025
Sponsor: University of Washington
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Opioid Use Disorder

Treatment

Patient Navigation and mHealth (PN+mHealth)

Clinical Study ID

NCT06027814
STUDY00016329
1R34DA057609-01
  • Ages > 18
  • All Genders

Study Summary

Polysubstance use involving opioids and methamphetamine is emerging as a new public health crisis. Patients with opioids and methamphetamine use often experience serious medical complications requiring hospitalization, which provides an opportunity to offer addiction treatment. Yet linkage to outpatient treatment post-discharge is suboptimal and methamphetamine exacerbates outcomes. The investigators propose to pilot test "MHealth Incentivized Adherence Plus Patient Navigation" (MIAPP) to promote treatment linkage and retention for patients with opioid use disorder (OUD) and methamphetamine use who initiate buprenorphine in the hospital. The investigators Aim is to perform a two-arm, pilot randomized clinical trial (n=40) comparing MIAPP + treatment-as-usual (TAU) versus TAU alone on outpatient medication for opioid use disorder (MOUD) linkage within 30 days (primary) and 90-day retention on medications (secondary) among hospitalized patients with OUD and methamphetamine use.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult greater than or equal to 18 years of age

  • Admitted to Harborview Medical Center (HMC) on any inpatient service

  • Initiated on buprenorphine for OUD while in the hospital or at the time of dischargeand planning to continue outpatient

  • Used methamphetamine within the past 30 days (any route of administration orfrequency)

  • Willing to be randomized to video-DOT

  • Willing and able to use a smartphone (study can provide) and work with patientnavigator

  • Discharge setting does not preclude the use of video-DOT (i.e., nursing home,inpatient psychiatry, etc.)

Exclusion

Exclusion Criteria:

  • Unable or unwilling to use smartphone (phones to be provided when needed)

  • Cognitive impairment (acute or chronic) resulting in inability to provide informedconsent

  • Currently incarcerated and will discharge to jail or prison

  • Plans to discontinue buprenorphine in the near future (<3 months)

  • Lives far away such that cannot keep study visit at 30 days post-discharge

  • Not English speaking

  • Behavioral risk per discretion of research staff

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: Patient Navigation and mHealth (PN+mHealth)
Phase:
Study Start date:
January 03, 2024
Estimated Completion Date:
September 22, 2026

Connect with a study center

  • Harborview Medical Center

    Seattle, Washington 98104
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.